市场调查报告书
商品编码
1368680
子宫肌瘤治疗药物市场 - 按药物类别(黄体素释放子宫内避孕器、避孕药、促性腺激素释放激素拮抗剂)、类型(黏膜下、壁内)、配销通路、全球预测,2023-2032 年Uterine Fibroid Treatment Drugs Market - By Drug Class (Progestin-releasing Intrauterine Device, Contraceptive, Gonadotropin-releasing Hormone Antagonist), Type (Submucosal, Intramural), Distribution Channel, Global Forecast, 2023-2032 |
从 2023 年到 2032 年,子宫肌瘤治疗药物市场规模预计将以 10% 的复合年增长率大幅成长。全球子宫肌瘤盛行率不断上升,引发了对有效药物干预措施的更高需求。
最近,人们越来越重视开发和提供先进的药物疗法,以有效控制症状并缩小肿瘤大小。根据妇女健康办公室的数据,20% 至 80% 的女性在 50 岁时会罹患肌瘤。因此,更加关註解决受影响个体的治疗需求已经为广泛的研发工作让路。此外,患者和医疗保健专业人员对可用治疗方案的认识不断提高也提振了产品需求。
子宫肌瘤治疗药物产业分为药物类别、类型、配销通路和区域。
按药物类别划分,促性腺激素释放激素拮抗剂细分市场的市场份额预计在2023 年至2032 年间将出现大幅增长。这可归因于促性腺激素释放激素(GnRH) 拮抗剂作为可行的非侵入性治疗选择的广泛使用。 GnRH 拮抗剂能够快速缓解症状并减轻月经出血量,因此越来越受到重视。有利的安全性和有限的副作用等好处将进一步促进该细分市场的成长。
医院配销通路领域的子宫肌瘤治疗药物行业在2022 年产生了可观的收入,预计到2032 年将强劲扩张。这种增长可归因于医院强大的基础设施和综合的患者护理方法,以确保有效的治疗和改善患者的状况结果。随着人们对微创手术的日益青睐,医院也越来越多地采用先进的药物解决方案来有效管理肌瘤。
从区域来看,由于医疗基础设施发展的激增、人们对子宫肌瘤的认识不断提高以及健康状况的患病率不断上升,预计到2032 年,亚太地区子宫肌瘤治疗药物行业将出现显着增长。微创手术的日益普及导致了针对该地区特定需求量身定制的新型药物解决方案的推出。
此外,旨在提高功效和尽量减少不利影响的持续研发活动将增强区域市场前景。举个例子,2022年7月,日本Kissei製药有限公司开始了GNRH拮抗剂林札戈利(KLH-2109)治疗子宫肌瘤的日本III期临床研究。
Uterine Fibroid Treatment Drugs Market size is set to witness substantial growth at 10% CAGR from 2023-2032. The escalating prevalence of uterine fibroids worldwide is triggering the heightened need for efficacious pharmaceutical interventions.
Of late, there has been growing emphasis on developing and providing advanced drug therapies to effectively manage symptoms and reduce tumor size. According to the Office on Women's Health, between 20% and 80% of women develop fibroids by the age of 50 years. Thus, the higher focus on addressing the therapeutic needs of affected individuals has made way for extensive R&D efforts. Moreover, the surging awareness among patients and healthcare professionals about available treatment options is also bolstering the product demand.
The uterine fibroid treatment drugs industry is segmented into drug class, type, distribution channel, and region.
By drug class, the market share from the gonadotropin-releasing hormone antagonist segment is set to witness considerable growth between 2023 and 2032. This can be attributed to the expanding utilization of gonadotropin-releasing hormone (GnRH) antagonists as viable non-invasive treatment options. With their ability to provide rapid symptomatic relief and alleviate heavy menstrual bleeding, GnRH antagonists are gaining significant prominence. Benefits, such as favorable safety profile and limited side effects will further contribute to the segment growth.
Uterine fibroid treatment drugs industry from the hospital distribution channel segment generated substantial revenue in 2022 and is expected to foresee robust expansion through 2032. The growth can be attributed to the robust infrastructure and integrated approach to patient care in hospitals for ensuring effective treatment and improved patient outcomes. With the growing preference for minimally invasive procedures, hospitals are also increasingly adopting advanced pharmaceutical solutions for effective fibroid management.
Regionally, the Asia Pacific uterine fibroid treatment drugs industry is projected to depict notable growth rate through 2032 fueled by the upsurge in healthcare infrastructure development, increasing awareness about uterine fibroids, and the rising prevalence of the health condition. The growing adoption of minimally invasive procedures has led to the introduction of novel pharmaceutical solutions tailored for specific needs in the region.
Moreover, the ongoing research and development activities aimed at enhancing the efficacy and minimizing adverse effects will augment the regional market outlook. To cite an instance, in July 2022, Japan-based Kissei Pharmaceutical Co., Ltd. began a Japanese Phase III clinical study for the GNRH antagonist linzagolix (KLH-2109) in uterine fibroids.